Chinese gene therapy ‘clinically cured’ patient with blood disorder thalassaemia, researchers say

A Chinese gene-editing pharmaceutical company says it has clinically cured a patient with beta thalassaemia, one of the most common inherited blood disorders, using genetic base-editing technology – a world first.

Shanghai-based CorrectSequence Therapeutics, along with collaborators from Guangxi Medical University, announced on Monday that they had cured an adolescent patient with transfusion-dependent beta thalassaemia.